First experience with filgotinib in the upper line of treatment in patients with ulcerative colitis
Drug profileGastroent Hepatol 2024; 78(2): 170–172. doi: 10.48095/ccgh2024170
Literaturepdf Milan Lukáš, Dana ĎuricováJaké bude vaše doporučení pro terapii těžké ulcerózní kolitidy?
Answer to the quizGastroent Hepatol 2024; 78(2): 178.
pdf Milan LukášTurcotʼs syndrome with abdominal complications
QuizGastroent Hepatol 2024; 78(5): 375–376.
pdf Milan LukášEtrasimod – the second generation S1P receptor modulators in ulcerative colitis therapy
Drug profileGastroent Hepatol 2024; 78(5): 415–416. doi: 10.48095/ccgh2024415
Literaturepdf Milan LukášAdherence to therapy in patients with inflammatory bowel disease on subcutaneous biologic therapy
Original articleGastroent Hepatol 2024; 78(6): 483–491. doi: 10.48095/ccgh2024483
SummaryLiteraturepdf Martin Kolář, Milan LukášTen years since the introduction of vedolizumab into clinical practice in inflammatory bowel diseases
Drug profileGastroent Hepatol 2024; 78(6): 492–493. doi: 10.48095/ccgh2024492
Literaturepdf Milan LukášSprávná odpověď na předchozí kvíz
Answer to the quizGastroent Hepatol 2024; 78(6): 502.
Literaturepdf Milan Lukáš